Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.72 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.72 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.72 |
| ▸ | EGFR | P00533 | 3/20 | 0.71 |
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | GRK5 | P34947 | 3/20 | 0.71 |
| ▸ | PLK4 | O00444 | 2/20 | 0.71 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.71 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.71 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.71 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.71 |
| ▸ | INSR | P06213 | 2/20 | 0.71 |
| ▸ | LCK | P06239 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047748 | 1.00 | KDR (0.72) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL16090262 | 0.94 | KDR (0.72) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL16137751 | 0.92 | KDR (0.77) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL2114114 | 0.92 | KDR (0.79) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL31672435 | 0.92 | KDR (0.79) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL13755225 | 0.92 | KDR (0.79) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL16137745 | 0.92 | KDR (0.79) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL16090414 | 0.92 | KDR (0.66) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL17480576 | 0.92 | KDR (0.70) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL16090296 | 0.91 | KDR (0.67) | KDRPRKAA1PRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | KDR 804/4885PRKAA1 69/4885PRKAA2 97/4885 |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | KDR 2025/4885PRKAA1 3253/4885PRKAA2 3135/4885 |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | KDR 2025/4885PRKAA1 3253/4885PRKAA2 3135/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | KDR 484/4885PRKAA1 46/4885PRKAA2 42/4885 |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | KDR 2025/4885PRKAA1 3253/4885PRKAA2 3135/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | KDR 327/4885PRKAA1 97/4885PRKAA2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.